Current intervention strategies for management of uterine fibroids in women of reproductive age are primarily surgical or radiological. There are limited options for medical therapy. Two small placebo-controlled trials showed that ulipristal acetate, a selective progesterone-receptor modulator (SPRM), reduced fibroid and uterine sizes in women with symptomatic fibroids.